Korlym
Payments companies reported to CMS as associated with Korlym. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Korlym, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Korlym
These are the largest totals companies reported as associated with Korlym. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hanford Yau | Orlando, FL | Endocrinology, Diabetes & Metabolism | $293,817.05 |
| Eduardo Luna | Edinburg, TX | Endocrinology, Diabetes & Metabolism | $277,408.39 |
| Alison Gracom | Irvine, CA | Medical | $277,347.88 |
| Bradley Eilerman | Florence, KY | Endocrinology, Diabetes & Metabolism | $276,274.98 |
| Kevin Pantalone | Cleveland, OH | Endocrinology, Diabetes & Metabolism | $259,876.31 |
| Christopher Lucci | Rockport, TX | Public Health & General Preventive Medicine | $255,521.04 |
| Robin Anderson | Portage, IN | Family | $255,116.47 |
| Rocio Harbison | Houston, TX | Endocrinology, Diabetes & Metabolism | $217,035.62 |
| Elena Christofides | Columbus, OH | Endocrinology, Diabetes & Metabolism | $204,868.82 |
| Allan Kennedy | Cleveland, OH | Endocrinology, Diabetes & Metabolism | $201,976.35 |
Prescribed Korlym?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.